Shanghai Henlius Biotech (HKSE:02696) Change In Receivables : HK$0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Change In Receivables?

Shanghai Henlius Biotech's change in receivables for the quarter that ended in Dec. 2023 was HK$0 Mil. It means Shanghai Henlius Biotech's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Shanghai Henlius Biotech's change in receivables for the fiscal year that ended in Dec. 2023 was HK$-310 Mil. It means Shanghai Henlius Biotech's Accounts Receivable increased by HK$310 Mil from Dec. 2022 to Dec. 2023 .

Shanghai Henlius Biotech's Accounts Receivable for the quarter that ended in Dec. 2023 was HK$709 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Shanghai Henlius Biotech's Days Sales Outstanding for the three months ended in Dec. 2023 was 40.29.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Shanghai Henlius Biotech's liquidation value for the three months ended in Dec. 2023 was HK$-6,409 Mil.

Shanghai Henlius Biotech Change In Receivables Historical Data

The historical data trend for Shanghai Henlius Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Change In Receivables Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-31.50

-404.16

-122.08

-180.24

-310.38

Shanghai Henlius Biotech Quarterly Data
	Dec17	Mar18	Jun18	Dec18	Mar19	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial												-	-	-	-	-

Shanghai Henlius Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0 Mil.

Shanghai Henlius Biotech (HKSE:02696) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Shanghai Henlius Biotech's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	708.581	/	1604.682	*	91
=	40.29

2. In Ben Graham's calculation of liquidation value, Shanghai Henlius Biotech's accounts receivable are only considered to be worth 75% of book value:

Shanghai Henlius Biotech's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1080.287	-	8434.424	+	0.75 * 708.581	+	0.5 * 828.383
=	-6,409

Shanghai Henlius Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech (HKSE:02696) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1801 Hongmei Road, 9th Floor, Innov Tower (Capitaland Building), Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Shanghai Henlius Biotech (HKSE:02696) Headlines

No Headlines